EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
April 27 2022 - 10:30AM
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company
committed to developing and delivering innovative medicines to
patients at radically lower prices, today announced that new data
on its lead oncology programs will be presented at the 2022
American Society of Clinical Oncology (ASCO) Annual Meeting taking
place from June 3 through June 7, 2022.
Presentations at ASCO will feature updated data on the
investigational PD-L1 inhibitor sugemalimab from the GEMSTONE-302
(NCT03789604) and GEMSTONE-201 (NCT03595657) trials as initial
systemic treatment for patients with Stage IV NSCLC and as
treatment for patients with relapsed or refractory ENKTL,
respectively. Data will also be presented on the activity of the
investigational EGFR-tyrosine kinase inhibitor (TKI) aumolertinib
from the Phase 3 AENEAS trial (NCT03849768) in patients with
advanced EGFR-mutated NSCLC and CNS metastases.
Overview of presentations featuring EQRx oncology
programs
Investigational Program |
Abstract Title |
Presentation Details |
Sugemalimab |
A protocol pre-specified interim overall survival (OS) analysis of
GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo
plus platinum-based chemotherapy (chemo) as first-line (1L)
treatment for patients (pts) with metastatic non-small cell lung
cancer (NSCLC)1 |
Abstract #9027, poster presentationSession: Lung Cancer – Non-Small
Cell MetastaticDATE: Monday, June 6, 2022 TIME: 9:00 a.m. – 12:00
p.m. ET |
Sugemalimab |
GEMSTONE-201: Pre-planned primary analysis of a multicenter,
single-arm, phase 2 study of sugemalimab (suge) in patients (pts)
with relapsed or refractory extranodal natural killer/T cell
lymphoma (R/R ENKTL)1 |
Abstract #7501, oral presentationSession: Hematologic Malignancies
– Lymphoma and Chronic Lymphocytic LeukemiaDATE: Friday, June 3,
2022 TIME: 2:00 p.m. – 5:00 p.m. ET |
Aumolertinib |
Aumolertinib activity in patients with CNS metastases and
EGFR-mutated NSCLC treated in the randomized double-blind phase III
trial (AENEAS)2 |
Abstract #9096, poster Session: Lung Cancer – Non-Small Cell
MetastaticDATE: Monday, June 6, 2022 TIME: 9:00 a.m. – 12:00 p.m.
ET |
About Sugemalimab Sugemalimab is a monoclonal
antibody targeting programmed death-ligand 1 (PD-L1) that is
currently being investigated in several ongoing clinical trials,
including studies in relapsed or refractory extranodal natural
killer/T cell lymphoma (ENKTL), Stage III non-small cell lung
cancer (NSCLC), Stage IV NSCLC, gastric cancer and esophageal
cancer. In October of 2020, the U.S. Food and Drug Administration
(FDA) granted sugemalimab Breakthrough Therapy Designation for the
treatment of adult patients with relapsed or refractory ENKTL.
Sugemalimab in combination with chemotherapy is approved by the
National Medical Products Administration (NMPA) of China for the
first-line treatment of patients with metastatic squamous and
non-squamous NSCLC. EQRx has partnered with
CStone Pharmaceuticals on global development of sugemalimab
with the goal of expanding access worldwide. EQRx holds the
development and commercialization rights to sugemalimab outside of
Greater China.
About AumolertinibAumolertinib is a
third-generation, irreversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR-
sensitizing and T790M resistance mutations, with high selectivity
over wild-type EGFR. Aumolertinib is being investigated in several
ongoing clinical trials, including studies in first- and
second-line EGFR-mutated non-small cell lung cancer (NSCLC).
Aumolertinib is approved by the National Medical Products
Administration (NMPA) of China for first-line and second-line
treatment of patients with locally advanced or metastatic EGFR
mutation-positive NSCLC. Aumolertinib was discovered by Hansoh
Pharmaceuticals, and EQRx has partnered with
Hansoh Pharmaceuticals on global development of aumolertinib
with the goal of expanding access worldwide. EQRx holds the
development and commercialization rights to aumolertinib outside of
Greater China.
About EQRxEQRx is a new type of pharmaceutical
company committed to developing and delivering innovative medicines
to patients at radically lower prices. Launched in January 2020,
EQRx is purpose-built, at scale, with a growing catalog of
medicines in development in high-cost drug categories and emerging
partnerships with leading payers and providers. Leveraging
cutting-edge science and technology and strategic partnerships with
stakeholders from across the healthcare system, EQRx aims to
provide innovative, patent-protected medicines more efficiently and
cost-effectively than ever before. To learn more, visit
www.eqrx.com and follow us on social media:
Twitter: @EQRxInc, LinkedIn,
Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains certain
forward-looking statements within the meaning of the federal
securities laws. These forward-looking statements may be identified
by the use of words such as “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “design,” “strategy,” “future,”
“opportunity,” “continue,” “aim,” “goal,” “plan,” “may,” “look
forward,” “should,” “will,” “would,” “will be,” “will likely
result,” and similar expressions. These forward-looking statements
include, but are not limited to, express or implied statements
regarding EQRx’s ability to develop and deliver innovative
medicines at radically lower prices, EQRx’s plans and timelines for
the clinical development and regulatory review of EQRx’s product
candidates both in and outside the U.S., and the therapeutic
potential and clinical benefits and tolerability of EQRx’s product
candidates. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to changes in the competitive
and highly regulated industries in which EQRx operates, the timing
and outcome of EQRx’s planned interactions with regulatory
authorities, changes in laws and regulations affecting EQRx’s
business, delay of any current and future clinical trials or the
development of aumolertinib, sugemalimab or EQRx’s other drug
candidates, the risk that the results of prior clinical trials may
not be predictive of future results in connection with future
clinical trials, EQRx’s ability to successfully demonstrate the
safety and efficacy of its drug candidates, the timing and outcome
of EQRx’s planned interactions with regulatory authorities;
obtaining, maintaining and protecting its intellectual property,
EQRx’s relationships with its existing and future collaboration
partners, risks associated with EQRx’s ability to otherwise
implement its business plans, including risks associated with its
growth strategy, obtaining regulatory approvals, and other risks
associated with its plans to create a new kind of pharmaceutical
company, the risk of downturns and a changing regulatory landscape
in the highly competitive healthcare and biopharmaceutical
industries, the size and growth of the markets in which EQRx
operates and its ability to offer innovative medicines at reduced
prices, and EQRx’s ability to operate as a public company. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section in EQRx’s
most recent Annual Report on Form 10-K or Quarterly Report on Form
10-Q, as well as any other filings with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and EQRx assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise.
Investors and others should note that we communicate with our
investors and the public using our website www.eqrx.com, including,
but not limited to, company disclosures, investor presentations and
FAQs, SEC filings, press releases, public conference call
transcripts and webcast transcripts. The information that we post
on our website could be deemed to be material information. As a
result, we encourage investors, the media and others interested
parties to review the information that we post there on a regular
basis. The contents of our website shall not be deemed incorporated
by reference in any filing with the SEC.
EQRx Contacts:
Media:Dan Budwick 1ABdan@1abmedia.com Adjoa
KyerematenMedia Relations Directormedia@eqrx.com
Investors:investors@eqrx.com
__________________________________1 EQRx and CStone
Pharmaceuticals have partnered on the global development of
sugemalimab. This presentation will be shared by CStone and its
collaborators.
2 EQRx and Hansoh Pharmaceuticals have partnered on the global
development of aumolertinib. This presentation will be shared by
Hansoh Pharmaceuticals and its collaborators.
EQRx (NASDAQ:EQRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
EQRx (NASDAQ:EQRX)
Historical Stock Chart
From Apr 2023 to Apr 2024